Brain Infarction
Conditions
Interventions
200 mg/day of Minocycline for 5 consecutive days
Placebo for 5 consecutive days
Sponsors
Takeshi Takahashi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Age >= 20 2) NIHSS Score >= 4 3) Ischemic Stroke patients within 6 to 24 hours from the onset and oral administration is available within the hours
Exclusion criteria
Exclusion criteria: 1) Hemorrhagic Stroke patients 2) Patients with evidence of other disease of the CNS 3) JCS >= 10 4) mRS before the onset >= grade 3 5) Patients who have known allergic response to tetracyclines 6) Patients with serious liver or renal diseases 7) Patients who have swallowing difficulties 8) During pregnancy or lactation 9) Patients who have serious pre-existing diseases 10) Patients who weigh over 100 kg
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of NIH Stroke Scale (NIHSS) scores on day 90 in subjects treated with 200 mg/day minocycline vs placebo. | — |
Secondary
| Measure | Time frame |
|---|---|
| Comparison of NIH Stroke Scale (NIHSS) scores on day 7 and day 30, as well as modified Rankin Scale (mRS) and Barthel Index (BI) scores on day 7, day 30, and day 90. | — |
Countries
Japan
Contacts
Public ContactTakeshi Takahashi
National Hospital Organization, Kumamoto Medical Center Department of Emergency and Critical Care Medicine
Outcome results
None listed